Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan

被引:21
|
作者
Okihara, Koji [1 ]
Kitamura, Koji [2 ,3 ]
Okada, Koichi
Mikami, Kazuya [1 ]
Ukimura, Osamu [1 ]
Miki, Tsuneharu [1 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan
[2] Saiseikai Kyoto Hosp, Dept Urol, Kyoto, Japan
[3] Meiji Oriental Coll Med, Dept Urol, Kyoto, Japan
关键词
prostate cancer; PSA; screening; PSA density;
D O I
10.1111/j.1442-2042.2007.01957.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The tendency of the results and quality control of prostate cancer screening serially performed for 10 years in an area of Japan were evaluated. Methods: A total of 39 213 men over 55 years of age have participated in the mass screening of prostate cancer in the Otokuni District, since 1995. Men whose prostate-specific antigen (PSA) levels were more than 4.1 ng/mL were indicated for the second screening. In the second screening, prostate-specific antigen density (PSAD) was calculated in men whose PSA levels ranged from 4.1 to 10.0 ng/mL. Results: Secondary screening was indicated in a total of 2428 subjects, of whom 1633 underwent it. Prostate cancer was diagnosed in 267 men. As a result of the evaluation of the indication of prostate biopsy according to the PSAD in 894 who underwent secondary screening for the first time, the procedure was judged to be unnecessary in 269 (35%) of 765 cases. Of these 269 subjects, 23 (8.5%) were found to have cancer. Clinically localized prostate cancer increased by 17%, and locally advanced and metastatic cancers decreased by 12% in the second compared with the first five years of the ten-year period. The exposure rate of PSA screening in the Otokuni District was 65% with the application for the rate of screenees whose PSA level was 4.1 ng/mL or above. Conclusions: The Japanese basic health screening system allows the determination of high-PSA exposure areas. Serial prostate cancer screening showed a tendency of stage migration in the screened cancer patients. The use of PSAD in secondary screening substantially reduces the necessity of prostate biopsy; however, the encouragement of PSA-positive individuals to periodically receive prostate cancer screening is essential to maintain the quality of the screening system.
引用
收藏
页码:156 / 160
页数:5
相关论文
共 50 条
  • [1] Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan - Comment
    Suzuki, Kazuhiro
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (02) : 161 - 161
  • [2] Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
    Kitagawa, Yasuhide
    Machioka, Kazuaki
    Yaegashi, Hiroshi
    Nakashima, Kazufumi
    Ofude, Mitsuo
    Izumi, Kouji
    Ueno, Satoru
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Mizokami, Atsushi
    Namiki, Mikio
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (06) : 833 - 837
  • [3] Prostate-specific antigen and screening for prostate cancer
    Han, M
    Gann, PH
    Catalona, WJ
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (02) : 245 - +
  • [4] Prostate-specific antigen for prostate cancer screening
    不详
    [J]. BJU INTERNATIONAL, 2023, 131 (03) : 266 - 266
  • [5] The Prostate Cancer Detection Rate on the Second Prostate Biopsy according to Prostate-Specific Antigen Trend
    Kim, Hyung-Sang
    Lee, Chang-Yong
    Lim, Dong-Hun
    Kim, Chul-Sung
    Baik, Seung
    [J]. KOREAN JOURNAL OF UROLOGY, 2012, 53 (10) : 686 - 690
  • [6] Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
    Martin, Richard M.
    Turner, Emma L.
    Young, Grace J.
    Metcalfe, Chris
    Walsh, Eleanor I.
    Lane, J. Athene
    Sterne, Jonathan A. C.
    Noble, Sian
    Holding, Peter
    Ben-Shlomo, Yoav
    Williams, Naomi J.
    Pashayan, Nora
    Bui, Mai Ngoc
    Albertsen, Peter C.
    Seibert, Tyler M.
    Zietman, Anthony L.
    Oxley, Jon
    Adolfsson, Jan
    Mason, Malcolm D.
    Davey Smith, George
    Neal, David E.
    Hamdy, Freddie C.
    Donovan, Jenny L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (17): : 1460 - 1470
  • [7] Update on screening for prostate cancer with prostate-specific antigen
    Schmid, HP
    Riesen, W
    Prikler, L
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) : 71 - 78
  • [8] Longitudinal screening for prostate cancer with prostate-specific antigen
    Smith, DS
    Catalona, WJ
    Herschman, JD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (16): : 1309 - 1315
  • [9] Prostate-specific Antigen Testing and Prostate Cancer Screening
    Djavan, Bob
    Eckersberger, Elisabeth
    Finkelstein, Julia
    Sadri, Helen
    Taneja, Samir S.
    Lepor, Herbert
    [J]. PRIMARY CARE, 2010, 37 (03): : 441 - +
  • [10] PROSTATE-SPECIFIC ANTIGEN IN SCREENING FOR PROSTATE-CANCER
    MAYER, FJ
    CRAWFORD, ED
    [J]. WESTERN JOURNAL OF MEDICINE, 1994, 160 (02): : 168 - 168